Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive ther...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Cancer J
Главные авторы: Shah, J J, Feng, L, Thomas, S K, Berkova, Z, Weber, D M, Wang, M, Qazilbash, M H, Champlin, R E, Mendoza, T R, Cleeland, C, Orlowski, R Z
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2016
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771967/
https://ncbi.nlm.nih.gov/pubmed/26871714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы